High volume and high permeability haemofiltration for sepsis: The evidence and the key issues

Care of the Critically Ill

Volumn 19, Issue 3, 2003, Pages 69-70+72

  Honore, Patrick M ^a   Zydney, Andrew ^b   Matson, James R ^c  

^a Clinique Saint Pierre of Ottignies   (Belgium)

^b The Pennsylvania State University   (United States)

^c MEDICAL CITY DALLAS HOSPITAL   (United States)

Author keywords

Cytokines; Haemofiltration; High permeability; High volume; Immune modulators; Review; Sepsis

Indexed keywords

AUTACOID; CYTOKINE; DROTRECOGIN; INTERLEUKIN 1BETA; POLYAMIDE; POLYSULFONE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD FILTRATION; CLINICAL TRIAL; DEVICE; DRUG EFFICACY; FILTER DESIGN; HEMODYNAMICS; HEMOFILTRATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTENSIVE CARE; MEMBRANE FILTER; NONHUMAN; PROCESS MODEL; REVIEW; SEPSIS;

EID: 0037530474     PISSN: 02660970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471-77.
2. Angus DC, Linde-Zwible WT, Lidieker J et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated cost of care. Crit Care Med 2001; 29: 1303-10.
3. Timmins AC, Hayes M, Yan E et al. The relationship between cardiac reserve and survival in critically ill patients receiving treatment aimed at achieving supranormal oxygen delivery and consumption. Postgrad Med J 1992; 68: 34-40.
4. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25: 1095-99.
5. Neugebauer E, Rixen D, Raum M, Schafer U. Thirty years of anti-mediator treatment in sepsis and septic shock - What have we learned? Langenbeck's Arch Surg 1998; 383: 26-34.
6. Daams J, Westerhoff H. The possible control of chaos in chronic inflammation. Clinical Theumatology 1996; 15 (Suppl 1), 34-39.
7. Callard R, George A, Stark J. Cytokines, chaos, and complexity. Immunity 1999; 11: 507-513.
8. Mohler R, Bruni C, Gandolfi A. A systems approach to immunology. Proc IEEE 1980; 68: 964-990.
9. Dinarello CA, Okusawa S, Gelfand FA. Interleukin-1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. Molecular and Cellular Mechanisms of Septic Shock, pp. 243-263, Alan R, Liss, Inc, 1989.
10. Waage A, Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor-α/cachectin in mice. J Exp Med 1988; 167: 1987-92.
11. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor-α and interleukin-1-β are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996; 183: 949-958.
12. Brouckaert P, Fiers W. Tumor necrosis factor and the systemic inflammatory response syndrome. In: Pathology of Septic Shock, Rietschel ET, Wagner H, Editors, Springer 1996. pp. 167-187.
13. Dinarello CA. Cytokines as mediators in the pathogenesis of septic shock. In: Pathology of Septic Shock, Rietschel ET, Wagner H, Editors, Springer 1996; pp. 133-165.
14. Fry DE. Microcirculatory arrest theory of SIRS and MODS. In Multiple Organ Failure, Eds: Baue AE, Faist E, Fry DE. Springer 2000; pp. 92-100.
15. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Heltebrand JD, Ely EW, Fisher CJ, PROWESS Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2002; 344: 699-709
16. Pradier O, Gerard C, Delvaux A, Lybin M, Abramowicz C, Capel P, Velu T, Goldman M. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur J Immunol 1993; 23: 2700-03.
17. Stouthard JML, Levi M, Hack CE, Veenhof CHN, Romijn HA, Sauerwein HP, Van Der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thrombosis and Haemostais 1996; 76: 738-742.
18. Asachenkov A, Marchuk G, Mohler R, Zuev S. Immunology and disease control: A systems approach. IEEE Trans Biomedical Engineering 1994; 41: 943-953.
19. Mohler R. Personal correspondence, April-May 1997.
20. Kramer P, Wigger W, Matthei D, Langescheid C, Mieger J, Fuchs C, Burne KW, Sheler F. Clinical experience with continuously monitored fluid balance in haemofiltration. Artif Organs 1978; 2: 147-9.
21. Coraim G, Wolmer E. Management of cardiac surgery patients with continuous arteriovenous hemofiltration. Continuous Arteriovenous Hemofiltration (CAVH). Int. Conf. On CAVH, Aachen 1984. pp. 103-110, Karger, Basel 1985.
22. Gotloib L, Barzilay E, Shustark A et al. Hemofiltration in septic ARDS. The artificial kidney as an artificial endocrine lung. Resuscitation 1986; 13: 123-132.
23. Brunet S, Leblanc M, Geadah D et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34: 486-492.
24. Uchino S, Bellomo R, Goldsmith D et al. Super high flux hemofiltration: A new technique for cytokine removal. Intensive Care Med 2002; 28: 651-655.
25. Uchino S, Bellomo R, Morimatsu H et al. Cytokine dialysis: An ex vivo study. ASAIO Journal 2002; 48: 650-653.
26. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomized trial. Lancet 2000; 355: 26-30.
27. Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, Hanique G, Matson JR. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting form septic shock. Crit Care Med 2000; 28: 3581-87.
28. Yekebas E, Eisenberger C, Ohnesorge H et al. Attenuation of sepsis-related immunoparalysis by continuous venovenous hemofiltration in experimental porcine pancreatitis. Crit Care Med 2001;29:1423-1430.
29. Abid O, Akca S, Haji-Michael P, Vincent JL. Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Crit Care Med 2000; 28: 947-949.
30. Carcillo J, Davis A, Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. JAMA 1991; 266: 1242-45.
31. Lee P, Matson J et al. Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993; 21: 914-924.
32. Bouman CSC, Van Olden RW, Stroutenbeek CP. Cytokine filtration and adsorption during pre- and post-dilution haemofiltration in four different membranes. Blood Purif 1998; 16: 261-8.
33. Mochizuki S, Zydney A. Effect of protein adsorption on the transport characteristics of asymmetric ultrafiltration membranes. Biotechnol Prog 1982; 8: 553-561.
34. Oudemans-Van Straaten H, Bosman R, Van Der Spoel J, Zandstra D. Outcome of critically ill patients treated with intermittent high-volume haemofiltration: A prospective cohort analysis. Intensive Care Med 1999; 25: 814-821.
35. Mochizuki S, Zydney A. Dextran transport through asymmetric ultrafiltration membranes: Comparison with hydrodynamic models. J Membrane Sci 1992; 68: 21-41.
36. Hoffmann JN, Werdan K, Hartl WH, Jochum M, Faist E, Inthorn E. Hemofiltrate from patients with severe sepsis and depressed left ventricular contractility contains cardiotoxic compounds. Shock 1999; 12: 174-180.
37. Heering P, Morgera S, Schmitz FJ, Schmitz G, Willers R, Schultheiss HP, Strauer BE, Grabensee B. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Medicine 1997; 23: 288-296.
38. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 10: 846-853.
39. Lee PA, Weger GW, Pryor RW, Matson JR. Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration (CAVH) therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1998; 26: 730-737.
40. Foundations of Systems Biology, Hiroaki Kitano, The MIT Press, October 2001. ISBN 0-262-11266-3.
41. Honoré PM, Matson JR. Short-term high-volume haemofiltration in sepsis: Perhaps the right way to start with. Crit Care Med 2002; 30: 1673-74.
42. Honoré PM, Matson JR. Haemofiltration, adsorption, sieving and the challenge of sepsis therapy design. Crit Care 2002; 6: 394-396.
43. Mink SN, Jha P, Wang R et al. Effects of continuous arterio-venous hemofiltration combined with systemic vasopressor therapy on depressed left ventricular contractility and tissue oxygen delivery in canine E. coli sepsis. Anesthesiology 1995; 83: 178-90.
44. Stein B, Pfenninger E, Grunert A et al. Influence of continuous hemofiltration on hemodynamics and cerebral blood volume in experimental endotoxic shock. Intensive Care Med 1990; 16: 494-499.
45. Gomez A, Wang R, Unruth H et al. Hemofiltration reverses left ventricular dysfunction during sepsis in dogs. Anesthesiology 1990; 73: 671-685.
46. Freeman BD, Yatsiv I, Natanson Ch et al. Continuous arterio-venous hemofiltration does not improve survival in a canine model of septic shock. J Am Coll Surg 1995; 180: 286-292.
47. Bellomo R, Kellum J, Gandhi CR et al. The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 2000; 161: 1429-36.
48. Rogiers P, Sun Q, Pauwels D, Dimopoulos G, Tu Z, Manhaeghe C, Vincent JL. Effects of hemofiltration with high cut-off membrane in ovine septic shock. Intensive Care Med 2001; 27: 262 [Abstract].
49. Rogiers P, Zhang H, Smail N, Pauwels D, Vincent JL. Continuous veno-venous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Crit Care Med 1999; 27: 1848-55.
50. Grootendorst AF, Van Bommel EFH, Van Der Hoeven B et al. High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med 1992; 18: 235-40.
51. Grootendorst AF, Van Bommel EFH, Van Leengoed LA et al. Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs. J Crit Care 1993; 8: 16.
52. John S, Griesbach D, Baumgartel et al. CVVH does not improve splanchnic microcirculation in septic shock compared to hemodialysis. Intensive Care Med 1998; 24: 75.
53. Gueugniaud PY, Bertin-Maghit M, Hirschauer C et al. Continuous veno-venous hemofiltration remove cytokines from the circulation of septic patients. Crit Care Med 1994; 22: 717.
54. Wakabayashi Y, Kamijou Y, Soma K et al. Removal of circulating cytokines by continuous hemofiltration in patients with systemic inflammatory response syndrome. Br J Surg 1996; 83: 393-94.
55. Tonnesen E, Hanson MB, Hohndorf K et al. Cytokines in plasma and ultrafiltrate during continuous arterio-venous hemofiltration. Anaesth Intensive Care 1993; 21: 752-58.
56. Heering P, Morgera S, Schmitz et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous veno-venous hemofiltration. Intensive Care Med 1997; 23: 288-96.
57. Sander A, Armbruster W, Sander B et al. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF-alpha plasma concentrations. Intensive Care Med 1997; 23: 878-84.
58. Hommel D, Hulin A. Cinetiques des cytokines (TNF-alpha, IFN-gamma, IL-6) au cours de l'hemofiltration a haut debit de courte duree. Reanim-Urg 1999; 8: 209-13.
59. Matamis D, Tsagourias M, Koletsosk et al. Influence of continuous hemofiltration related hypothermia on haemodynamic variables and gas exchanges in septic patients. Intensive Care Med 1994; 20: 431-36.
60. Hoffmann JN, Hartl WH, Deppish R et al. Effects of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis. Intensive Care Med 1996; 22: 1360-67.
61. Kellum J, Johnson J, Kramer D et al. Diffusive versus convective therapy: Effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome. Crit Care Med 1998; 26: 1995-2000.
62. Grootendorst AF, Bouman CSC, Hoeben KHN et al. The role of continuous renal replacement therapy in sepsis and multiorgan failure. Am J Kidney Dis 1996; 28: 50-57.
63. Cole L, Bellomo R, Journois D et al. High-volume hemofiltration in human septic shock. Intensive Care Med 2001; 27: 978-86.